Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.25
+0.29 (4.17%)
At close: May 13, 2026, 4:00 PM EDT
7.23
-0.02 (-0.28%)
After-hours: May 13, 2026, 6:28 PM EDT
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
483.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 299.77M |
| ADC Therapeutics | 79.18M |
| Assembly Biosciences | 71.10M |
| Enanta Pharmaceuticals | 66.98M |
| Prelude Therapeutics | 12.14M |
| Ovid Therapeutics | 7.25M |
| Neurogene | 925.00K |
| Lyell Immunopharma | 31.00K |
FULC News
- 3 days ago - Fulcrum Therapeutics price target raised to $8 from $7 at BofA - TheFly
- 5 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Fulcrum Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 16 days ago - Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c) - TheFly
- 16 days ago - Fulcrum Therapeutics CFO Alan Musso to retire - TheFly
- 16 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 - GlobeNewsWire
- 16 days ago - Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors - GlobeNewsWire
- 23 days ago - Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET - GlobeNewsWire